3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
2
Carcinoma, Hepatocellular
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
3
Paclitaxel
3
Carboplatin
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
olaparib
1
lenvatinib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
durvalumab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Taxes
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Endometrial Neoplasms
×
lenvatinib
×
Clear all
NCT03517449
2026-03-19
MK-3475-775
Eisai Inc.
Phase 3
Completed
827 enrolled
34 charts
1 FDA